Trial Profile
A Phase III, Open-Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia [EXTENSION OF 700239254]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Ferumoxytol (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Sponsors AMAG Pharmaceuticals
- 04 Dec 2018 Results assessing the efficacy of ferumoxytol in anemia patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 03 Dec 2018 According to AMAG Pharmaceuticals Media Release, data from this study were Presented at the American Society of Hematology Annual Meeting.
- 03 Dec 2018 Results published in the AMAG Pharmaceuticals Media Release